During kidney diseases, PDGFR‐β is upregulated, and blocking PDGFR‐β signaling using either specific antibodies (Takahashi et al, 2005) or non‐specific tyrosine‐kinase receptor inhibitors such as imatinib ameliorated kidney injury in various renal disease models (Lassila et al, 2005; Wang et al, 2005; Zoja et al, 2006; Floege et al, 2008). The gene discussed is PDGFRB; the disease is kidney disorder.